The global antinuclear antibody test market is envisioned to garner $ 4,999.4million by 2030, growing from $ 1,294.9 million in 2021 at a CAGR of 14.97% from 2022 to 2031.
An anti-nuclear antibody (ANA) test is a blood test performed to find out whether there are any autoantibodies present in the patient showing symptoms of autoimmune diseases. Autoantibodies are usually made by the body against its own cells, present in the serum.
The market expansion of anti-nuclear antibody testing is driven by government healthcare insurance, an increase in autoimmune disorders awareness campaigns, and reimbursement regulations. For instance, the World Lupus Federation (WLF) is an alliance of about 250 lupus organizations from 75 nations across six continents with the goal of helping lupus patients. WLF promotes lupus awareness among the general public and gives lupus patients access to improved medical care facilities like providing assistance in conducting antinuclear antibody tests of the patients.
The individual in charge of doing ANA tests needs to be knowledgeable about both technology and the condition. A person cannot complete the test without comprehending both. The greatest barrier for the global market in the anticipated term is expected to be a lack of skilled staff to operate the testing kits. Additionally, everyone cannot afford the test because of its high cost, which is expected to impede the market's growth throughout the projected time.
Antinuclear antibody testing is anticipated to benefit from the Covid-19 pandemic and experience substantial growth during the pandemic stage. Antinuclear antibody testing has become increasingly popular, which is the main cause of this market growth. These tests demonstrate the existence of autoimmune illnesses in a person's body, making their detection vital. Additionally, the market is developing due to the rising prevalence of autoimmune illnesses in the COVID positive patients. All of these factors support market expansion during the Covid-19 epidemic.
The key players profiled in this report include Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc.
An anti-nuclear antibody (ANA) test is a blood test performed to find out whether there are any autoantibodies present in the patient showing symptoms of autoimmune diseases. Autoantibodies are usually made by the body against its own cells, present in the serum.
The market expansion of anti-nuclear antibody testing is driven by government healthcare insurance, an increase in autoimmune disorders awareness campaigns, and reimbursement regulations. For instance, the World Lupus Federation (WLF) is an alliance of about 250 lupus organizations from 75 nations across six continents with the goal of helping lupus patients. WLF promotes lupus awareness among the general public and gives lupus patients access to improved medical care facilities like providing assistance in conducting antinuclear antibody tests of the patients.
The individual in charge of doing ANA tests needs to be knowledgeable about both technology and the condition. A person cannot complete the test without comprehending both. The greatest barrier for the global market in the anticipated term is expected to be a lack of skilled staff to operate the testing kits. Additionally, everyone cannot afford the test because of its high cost, which is expected to impede the market's growth throughout the projected time.
Antinuclear antibody testing is anticipated to benefit from the Covid-19 pandemic and experience substantial growth during the pandemic stage. Antinuclear antibody testing has become increasingly popular, which is the main cause of this market growth. These tests demonstrate the existence of autoimmune illnesses in a person's body, making their detection vital. Additionally, the market is developing due to the rising prevalence of autoimmune illnesses in the COVID positive patients. All of these factors support market expansion during the Covid-19 epidemic.
The key players profiled in this report include Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antinuclear antibody test market analysis from 2021 to 2031 to identify the prevailing antinuclear antibody test market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the antinuclear antibody test market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global antinuclear antibody test market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
- Reagents Assay Kits
- Systems
- Software Services
By Technique
- ELISA
- Immunofluorescence Assay
- Multiplex Assay
By Application
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Sjogren’s Syndrome
- Scleroderma
- Others
By End-use
- Hospitals
- Clinical Laboratories
- Physician Office Laboratories
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest Of Asia Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA
Key Market Players
- erba diagnostics mannheim gmbh
- Bio-Rad Laboratories, Inc.
- Trinity Biotech Plc.
- Thermo Fisher Scientific, Inc.
- Antibodies Incorporated
- euroimmun medizinische labordiagnostika ag
- Immuno Concepts NA Ltd.
- Inova Diagnostics, Inc.
- ZEUS Scientific, Inc.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT
CHAPTER 5: ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE
CHAPTER 6: ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION
CHAPTER 7: ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE
CHAPTER 8: ANTINUCLEAR ANTIBODY TEST MARKET, BY REGION
CHAPTER 9: COMPANY LANDSCAPE
CHAPTER 10: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Antinuclear Antibody Test Market," the antinuclear antibody test market size was valued at $1.3 billion in 2021, and is estimated to reach $5 billion by 2031, growing at a CAGR of 15% from 2022 to 2031.Antinuclear antibodies can be found in a person's blood serum using an antinuclear antibody test. Antinuclear antibody (ANA) testing is used to identify autoimmune illnesses that damage the tissues and organs of the body. These tests check the blood serum for antinuclear antibodies. Antibodies made by the human immune system defend the body from invaders such as viruses and bacteria. Antinuclear antibodies, on the other hand, attack the patient's own healthy cells and result in autoimmune illness. Systemic lupus erythematosus, rheumatoid arthritis, scleroderma, and Sjogren's syndrome are just a few of the major health problems that can be brought on by autoimmune illnesses.
Rapidly increasing autoimmune disease incidences among people, across the globe, is expected to be the main factor driving the global antinuclear autoimmune test market. Additionally, the majority of people have health insurance due to their rising health related awareness through government campaigns. This factor is predicted to accelerate the expansion of the market for antinuclear antibodies throughout the projected period. These factors are anticipated to propel the antinuclear antibody test market growth.
However, the market for antinuclear antibody tests may experience growth restrictions due to tight guidelines for medical device clearance and the need for large cash to purchase expensive equipment. Lack of qualified medical personnel will hinder market expansion.
The increase in people choosing medical insurance for financial security is anticipated to be a key driving factor for antinuclear antibody test market over the anticipated timeframe. Several governmental organizations are putting into action a number of initiatives to promote health insurance plans to give families financial security, which is anticipated to spur market expansion in the upcoming years. Additionally, it is predicted that the antinuclear antibody market will have plenty of growth opportunities in the predicted timeframe due to rising investments in the establishment and advancements of medical laboratories, particularly in developing countries where investments in healthcare infrastructure and test kits are rising.
The global antinuclear antibody test market share is segmented based on product, technique, application, end-use industry, and region. By product, the market is sub-segmented into reagents & assay kits, systems and software & services. By technique, ELISA, immunofluorescence assay and multiplex assay. By application, rheumatoid arthritis, systemic lupus erythematosus, sjogren’s syndrome, scleroderma and others. By end use, hospitals, clinical laboratories, physician office laboratories and others. By region, the market is analysed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in the antinuclear antibody test market report include Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc.
The report offers a comprehensive analysis of the global antinuclear antibody test market trends by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market. The report also sheds light on the present scenario and upcoming trends & developments that are contributing to the growth of the market. Moreover, restraints and challenges that hold power to obstruct the market growth are also profiled in the report along with the Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market.
Impact of Covid-19 on the Global Antinuclear Antibody Test Industry
- The global antinuclear antibody testing market is anticipated to have a large uptick as a result of the pandemic. Due to the novel coronavirus outbreak, the majority of industrial sites have been closed, and many businesses have implemented work-from-home policies. However, healthcare institutions have taken numerous actions and are actively working on the creation of numerous vaccines and treating patients.
- The demand for antinuclear antibody test kits is anticipated to rise as more people conduct antinuclear antibody tests to diagnose autoimmune illnesses during the pandemic.
Key Findings of the Study
- Based on product, the reagents & assay kits sub-segment emerged as the global leader in 2021 and is anticipated to be the fastest growing sub-segment during the forecast period.
- Based on technique, the ELISA sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years.
- Based on application, the rheumatoid arthritis sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years.
- Based on end-use industry, the hospital sub-segment emerged as the global leader in 2021 and physician office laboratories sub-segment is predicted to show the fastest growth in the upcoming years.
- Based on region, the North America market registered the highest market share in 2021 and is projected to maintain the position during the forecast period.
Companies Mentioned
- Erba Diagnostics Mannheim GmbH
- Bio-Rad Laboratories, Inc.
- Trinity Biotech plc.
- Thermo Fisher Scientific, Inc.
- Antibodies Incorporated
- Euroimmun Medizinische Labordiagnostika AG
- Immuno Concepts Na Ltd.
- Inova Diagnostics, Inc.
- Zeus Scientific, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
